Literature DB >> 17142178

Pleural dissemination of thymoma showing tumor regression after combined corticosteroid and tacrolimus therapy.

Takafumi Taguchi1, Tadashi Suehiro, Kagawa Toru, Naoko Ogami, Hiroshi Takata, Kozo Hashimoto.   

Abstract

We present the case of an elderly woman with myasthenia gravis who had pleural dissemination of thymoma reduced by treatments with a moderate dose of corticosteroids and a conventional dose of tacrolimus. A maintenance dose of prednisolone for myasthenia gravis could not shrink the size of the disseminated thymoma, but prednisolone (>30 mg daily) succeeded in reducing the size of the tumor. Moreover, a combination with tacrolimus enabled the daily dose of prednisolone to be tapered off without recurrence of myasthenia gravis, and the disseminated thymoma almost disappeared. A moderate or higher dosage of corticosteroids with tacrolimus may, in some cases, be an effective procedure for pleural dissemination of thymoma. Treatment should be undertaken on a trial basis for patients not indicated for surgery, radiotherapy, or chemotherapy.

Entities:  

Year:  2006        PMID: 17142178     DOI: 10.1016/j.ejim.2006.04.014

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  3 in total

Review 1.  The clinical features, diagnosis and management of recurrent thymoma.

Authors:  Taobo Luo; Hongguang Zhao; Xinming Zhou
Journal:  J Cardiothorac Surg       Date:  2016-08-31       Impact factor: 1.637

2.  Local radiotherapy for pleural dissemination of thymic tumors after initial treatment.

Authors:  Dai Okazaki; Yuta Shibamoto; Takeshi Yanagi; Satoshi Ishikura; Takuhito Kondo; Yuki Yamada; Masanari Niwa
Journal:  J Radiat Res       Date:  2021-07-10       Impact factor: 2.724

Review 3.  The role of surgery in the management of locally advanced and metastatic thymoma: a narrative review.

Authors:  Catherine Wagner; Elliot Wakeam; Shaf Keshavjee
Journal:  Mediastinum       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.